MedRx Co., Ltd (TYO:4586)
65.00
0.00 (0.00%)
May 29, 2026, 3:30 PM JST
MedRx Revenue
MedRx had revenue of 5.00M JPY in the quarter ending March 31, 2026, with 150.00% growth. This brings the company's revenue in the last twelve months to 131.00M, down -49.42% year-over-year. In the year 2025, MedRx had annual revenue of 128.00M, down -50.19%.
Revenue (ttm)
131.00M
Revenue Growth
-49.42%
P/S Ratio
29.46
Revenue / Employee
6.24M
Employees
21
Market Cap
3.86B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 128.00M | -129.00M | -50.19% |
| Dec 31, 2024 | 257.00M | 228.00M | 786.21% |
| Dec 31, 2023 | 29.00M | -30.00M | -50.85% |
| Dec 31, 2022 | 59.00M | 51.00M | 637.50% |
| Dec 31, 2021 | 8.00M | -107.00M | -93.04% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Pharma Foods International | 67.84B |
| Fuso Pharmaceutical Industries,Ltd. | 62.17B |
| Nippon Chemiphar | 33.09B |
| Morishita Jintan | 12.69B |
| Wakamoto Pharmaceutical | 9.43B |
| Taiko Pharmaceutical | 6.16B |
| WDB coco | 4.82B |
| SymBio Pharmaceuticals | 1.28B |